Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF V600E inhibition in anaplastic thyroid cancer.

The New England journal of medicine - 14 Feb 2013

Rosove Michael H, Peddi Parvin F, Glaspy John A

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRAF gene
Share to Indoles
Share to Mutation
Share to Proto-Oncogene Proteins B-raf

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Sulfonamides

Share to Thyroid Carcinoma, Anaplastic

Share to Thyroid Neoplasms

Share to Vemurafenib

Source

Identifiers

PMID: 23406047
DOI: 10.1056/NEJMc1215697

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF V600E inhibition in anaplastic thyroid cancer.PMID 23406047Read ↗

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancerSemantic proximity Read ↗

Targeting BRAF in thyroid cancer.Semantic proximity Read ↗

BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma.Semantic proximity Read ↗

Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Recent advances in anaplastic thyroid cancer management.Semantic proximity Read ↗

Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement.Semantic proximity Read ↗

BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future PerspectivesSemantic proximity Read ↗

BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series.Semantic proximity Read ↗

Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.Semantic proximity Read ↗

Advances in targeted therapy for anaplastic thyroid carcinoma.Semantic proximity Read ↗

Combination therapy with BRAF and MEK inhibitors for anaplastic thyroid cancer: A report of two cases.Semantic proximity Read ↗

BRAF is a therapeutic target in aggressive thyroid carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.